Treatment for meningeal carcinomatosis in breast cancer.
Forty breast cancer patients with meningeal carcinomatosis were treated with a combined program of whole brain irradiation therapy with intrathecal and intraventricular methotrexate and citrovorum factor rescue. Responses were seen in 26 patients (65%); 13 patients (35%) failed to respond. The median survival time for the responding patients was six months, and for the nonresponders, one month. Factors affecting response and survival included pretreatment spinal fluid glucose, protein, and duration of CNS-related symptomatology prior to onset of therapy. In contrast, pretreatment CSF tumor cell count, CEA and initial CNS functional status did not appear to have prognostic significance. The authors conclude that following intensive therapy there can be much improvement in the quality of life and disease-free survival in breast cancer patients with meningeal carcinomatosis.
D001921:Brain / Q000528:radiation effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002277:Carcinoma / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D005260:Female; D006801:Humans; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D002955:Leucovorin / Q000008:administration & dosage; D008577:Meningeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary*; D008727:Methotrexate / Q000008:administration & dosage; D010166:Palliative Care; D011379:Prognosis; D011788:Quality of Life
D002955:Leucovorin; D008727:Methotrexate